Back to Press Releases

Revance Expands Leadership Team with Key Executive Appointments

Nashville, TN, October 1, 2025 – Revance, a fast-growing global leader in aesthetics and skincare, today announced the appointments of Scott Leffler as Chief Financial Officer and Kira Schwartz as Chief Legal Officer, effective immediately. Revance also announced the promotion of Nick Crowe to Chief Operating Officer, effective immediately. 

The seasoned leaders will join Revance’s Executive Leadership Team and report to Nadeem Moiz, Chief Executive Officer, effective today.

These appointments underscore an important step in the Company’s next chapter of growth, as Revance continues to strengthen its leadership team to help accelerate innovation, increase operational excellence, and advance its mission to become the most dynamic, science-backed, and customer-focused aesthetics and skincare company in the industry.

 “As we accelerate our pace of growth and transformation across our people, processes and portfolio of products, we are thrilled to also continue to expand our talented bench of leaders,” said Moiz. “On behalf of Revance, we welcome Scott and Kira to the team, while recognizing Nick’s well deserved promotion. Together, they bring deep expertise across finance, legal and operations that will be instrumental as we advance our market-leading position.”  

Scott Leffler, Chief Financial Officer 

Leffler will lead the finance team, overseeing accounting, FP&A, treasury, tax, capital allocation, and risk management. He will play a key role in guiding financial planning and investments to support strategic growth and long-term goals. Leffler brings over 20 years of finance leadership in public and private equity-backed health and science companies. He most recently served as CFO at Myriad Genetics, where he led a 200-person finance team, strengthened risk management, and enhanced investor engagement. He also held CFO roles at Clover Health, Sotera Health, and Exal Corporation (now Trivium Packaging). Leffler holds a B.A. in economics from Yale University and an M.B.A. from Emory University. Leffler is a Certified Public Accountant.

Kira Schwartz, Chief Legal Officer 

Schwartz will lead Revance’s legal and compliance functions, overseeing corporate governance, transactions, dispute resolution, regulatory matters, and intellectual property. She will help ensure the business grows with strong legal, ethical, and operational foundations. Schwartz brings over 20 years of legal and executive leadership in the pharmaceutical and biotechnology sectors,  most recently serving as Executive Vice President, General Counsel, and Corporate Secretary at Odyssey Therapeutics. She previously held senior roles at Prevail Therapeutics, Pfizer, and Cleary Gottlieb Steen & Hamilton LLP. Schwartz earned her Juris Doctor from Yale Law School and her B.A. in economics, summa cum laude, from Tufts University. She is a member of the New York State Bar. 

Nick Crowe, Chief Operating Officer 

Crowe will oversee day-to-day operations, supply chain, production and quality, while streamlining processes, and driving strategic initiatives to support growth. He will focus on  scaling the business, while ensuring operational excellence and advancing Revance’s commitment to innovation and customer-focused growth. Crowe has been with Revance for more than 10 years, most recently as Chief Accounting Officer, where he oversaw significant enterprise growth. Prior to that, Crowe was a senior manager in Consulting and Audit at Blackburn, Childers & Steagall, PLC., where he specialized in serving manufacturing clients and medical practices over nine years. Crowe holds a degree in Business Administration with concentrations in accounting and logistics and transportation from the University of Tennessee.  Crowe is a Certified Public Accountant.

###

About Revance 

Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments. 

Focused on skin science for life, Revance's extensive portfolio includes leading brands within the aesthetics, consumer skincare, and therapeutics categories. 

Aesthetics offerings include: DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection; the RHA® Collection of dermal fillers by Teoxane SA; SkinPen®, an industry-leading microneedling device; MicroPen EVO™, an FDA-cleared microneedling device; ProGen PRP Eclipse, the gold standard in Platelet-Rich Plasma; and Biojuve®, a clinically proven living microbe technology, among others. Revance's strong consumer skincare portfolio includes brands such as PanOxyl®, Blue Lizard®, StriVectin®, Sarna®, Zeasorb®, Desenex®, and Keri®. 

Learn more at Revance.com.

Media Contact:
ICR
Revance@icrinc.com


IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection

Indications

(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION

Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:

Glabellar lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (6%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Facebook Instagram Twitter LinkedIn

FOR CUSTOMER SERVICE, PRODUCT INFORMATION, NEW ACCOUNTS OR ADVERSE EVENTS CALL: 877-3REV-NOW

1222 DEMONBREUN ST

20TH FLOOR

NASHVILLE, TN 37203

©2025 REVANCE.
RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The TEOXANE RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.
CORP-00147

SOCIAL MEDIA COMMUNITY GUIDELINES PRIVACY POLICY TERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.